Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Linder, Katherine; Gandhiraj, Deepthi; Hanmantgad, Madhura; Seiter, Karen; Liu, Delong
• Is Part Of: Experimental hematology & oncology. Volume 5:Issue 1(2015)
• Page Start: 1
• Page End: 4
• Publication Date: 2015-12
• Subjects: Hematology, Experimental -- Periodicals; Oncology, Experimental -- Periodicals; Hematologic Diseases -- Periodicals; Neoplasms -- Periodicals; 616.1502705
• DOI: 10.1186/s40164-016-0051-4
• Languages: English
• ISSNs: 2162-3619

Abstract

Abstract Background The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy. Case presentation We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens. Conclusion This highly refractory pre-B Ph− ALL was induced to complete remission after one course of single agent blinatumomab.